Copyright
©The Author(s) 2015.
World J Gastroenterol. Aug 28, 2015; 21(32): 9598-9606
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9598
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9598
Figure 3 Distribution of Ishak fibrosis scores for the entecavir and lamivudine arms at baseline and post-treatment.
The green areas represent the percentage of patients who had an Ishak fibrosis score of 0 post-treatment. ETV: Entecavir; LAM: Lamivudine; ADV: Adefovir.
-
Citation: Wang JL, Du XF, Chen SL, Yu YQ, Wang J, Hu XQ, Shao LY, Chen JZ, Weng XH, Zhang WH. Histological outcome for chronic hepatitis B patients treated with entecavir
vs lamivudine-based therapy. World J Gastroenterol 2015; 21(32): 9598-9606 - URL: https://www.wjgnet.com/1007-9327/full/v21/i32/9598.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i32.9598